Following an impressive market entry for the new wound care product Omnigen®, an innovative dry preserved amniotic membrane-derived therapy, into NHS and private healthcare ophthalmic market, NuVision Biotherapies are extending their reach by working with MED Surgical as their new distributor for the whole of Ireland.
MED Surgical have an established and enviable record of delivering quality products into the Irish healthcare market for over 20 years. Their skilled and experienced representatives will be working with ophthalmic surgeons in order to facilitate access to Omnigen® for the treatment of ocular surface disorders. Both companies look forward to working together to help preserve and save sight.
Dr Andrew Hopkinson, CEO NuVision Biotherapies Ltd, said;
“We are all very excited to work with MED Surgical to provide access to Omnigen for the people of Ireland. Our experience in England has been very positive, with over 30 hospitals, NHS and private already using Omnigen to help restore and retain patients sight. Surgeons in England have found Omnigen to be convenient, easy to use and effective in the treatment of ocular surface disorders, and we look forward to offering the same opportunity for use to Irish Ophthalmic Surgeons”
To find out more about NuVision, please go to their website.
